Based on the recently published PAR2 crystal structure, a novel series of PAR2 antagonists were developed - namely the AZ series. However these require further target validation and elucidation of there pharmacological properties, and from these novel derivatives will be developed.
Inhibiting the GPCR receptor PAR2 for the treatment of arthritis and inflammatory disease
AZ-series appears to be a selective PAR2 antagonist, capable of inhibiting several downstream signalling pathways. Further work ex-vivo is on-going.
|Short title||PAR2 antagonists|
|Effective start/end date||5/02/18 → 31/07/21|